These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 22722516)
1. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. Richter C; Effenberger S; Bschor T; Bonnet U; Haasen C; Preuss UW; Heinz A; Förg A; Volkmar K; Glauner T; Schaefer M J Clin Psychopharmacol; 2012 Aug; 32(4):558-62. PubMed ID: 22722516 [TBL] [Abstract][Full Text] [Related]
2. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
3. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Müller CA; Schäfer M; Schneider S; Heimann HM; Hinzpeter A; Volkmar K; Förg A; Heinz A; Hein J Pharmacopsychiatry; 2010 Jul; 43(5):184-9. PubMed ID: 20503149 [TBL] [Abstract][Full Text] [Related]
6. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Consoli D; Bosco D; Postorino P; Galati F; Plastino M; Perticoni GF; Ottonello GA; Passarella B; Ricci S; Neri G; Toni D; Cerebrovasc Dis; 2012; 34(4):282-9. PubMed ID: 23128439 [TBL] [Abstract][Full Text] [Related]
7. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Marra D; Warot D; Berlin I; Hispard E; Notides C; Tilikete S; Payan C; Lépine JP; Dally S; Aubin HJ Alcohol Clin Exp Res; 2002 Oct; 26(10):1545-52. PubMed ID: 12394288 [TBL] [Abstract][Full Text] [Related]
8. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z; Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Förg A; Hein J; Volkmar K; Winter M; Richter C; Heinz A; Müller CA Alcohol Alcohol; 2012; 47(2):149-55. PubMed ID: 22215002 [TBL] [Abstract][Full Text] [Related]
10. Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. Martinotti G; Reina D; Di Nicola M; Andreoli S; Tedeschi D; Ortolani I; Pozzi G; Iannoni E; D'Iddio S; Janiri L Alcohol Alcohol; 2010; 45(5):449-55. PubMed ID: 20595193 [TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J; Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752 [TBL] [Abstract][Full Text] [Related]
12. Levetiracetam in the treatment of alcohol dependence: toward the end of the story? Le Strat Y Alcohol Clin Exp Res; 2012 Aug; 36(8):1309-10. PubMed ID: 22823576 [TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Fertig JB; Ryan ML; Falk DE; Litten RZ; Mattson ME; Ransom J; Rickman WJ; Scott C; Ciraulo D; Green AI; Tiouririne NA; Johnson B; Pettinati H; Strain EC; Devine E; Brunette MF; Kampman K; A Tompkins D; Stout R; Alcohol Clin Exp Res; 2012 Aug; 36(8):1421-30. PubMed ID: 22324516 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Guardia J; Caso C; Arias F; Gual A; Sanahuja J; Ramírez M; Mengual I; Gonzalvo B; Segura L; Trujols J; Casas M Alcohol Clin Exp Res; 2002 Sep; 26(9):1381-7. PubMed ID: 12351933 [TBL] [Abstract][Full Text] [Related]
15. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). Borggraefe I; Bonfert M; Bast T; Neubauer BA; Schotten KJ; Maßmann K; Noachtar S; Tuxhorn I; May TW; Heinen F; Eur J Paediatr Neurol; 2013 Sep; 17(5):507-14. PubMed ID: 23642492 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. de Bejczy A; Nations KR; Szegedi A; Schoemaker J; Ruwe F; Söderpalm B Alcohol Clin Exp Res; 2014 Sep; 38(9):2427-35. PubMed ID: 25257291 [TBL] [Abstract][Full Text] [Related]